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Abstract - Viruses are the main cause of opportunistic infections after kidney transplantation. The aim of this study was to 
determine the prevalence of cytomegalovirus (CMV), Epstein-Barr virus (EBV), B. K. virus (BKV) and John Cunningham 
virus (JCV) infections in renal transplant recipients (RTR). This retrospective study of 112 RTR investigated the presence 
of CMV, EBV and polyomaviruses DNA in plasma and/or urine by PCR. The visualization of PCR products was performed 
by electrophoresis on 2% agarose gel stained with ethidium bromide and photographed under a UV light. The chi-square 
test was used for statistical analysis. CMV DNA was detected in 14/112 (12.5%), EBV DNA in 4/49 (8.16%), BKV DNA in 
10/31 (32.26%) and JCV DNA in 3/31 (9.68%) RTR. These results show that CMV infection is more often present in RTR 
compared to other investigated viral infections. In the light of these results, molecular testing could be useful in identifying 
recipients at high risk of symptomatic post-transplant viral infection.
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INTRODUCTION
The human body has a complex system of protec-
tive  mechanisms  to  prevent  infection  which  in-
volves both adaptive and innate immune systems 
(e.g.  skin,  mucus  membranes).  Immunocompro-
mised patients have one or more defects in their 
body’s defense against microbial invaders. They can 
become infected with pathogens capable of infect-
ing immunocompetent individuals, but also with 
opportunist microbes that do not cause diseases in 
healthy individuals, but are capable of infecting an 
immunocompromised person, often leading to se-
vere and life-threatening infections with fatal con-
sequences. Different types of defects can predispose 
individuals to infections with different pathogen, 
depending on the critical mechanisms operating in 
defense against individual types of microorganisms 
(Fishman, 2007; Blair et al., 2008).
Solid  organ  and  bone  marrow  transplantation 
are among the most important advances in modern 
medicine. Their success depends to a great degree on 
the ability to control and manage the adverse effects 
of immunosuppressive regimens, primarily the sus-
ceptibility to infection as long as immunosuppres-
sion is applied. Although renal, cardiac and hepatic 
allografts would appear to employ very different pro-
cedures, they result in similar patterns of transplant-
related infection. The reason for this apparent para-
dox is that the risk of infection is largely the result of 
the immunosuppressive treatment given to prevent 
acute and chronic rejection. This treatment is in prin-
ciple standardized for all solid organ transplants. The 1286 MAJA ĆUPIĆ ET AL.
risk of infection increases with the extent and dura-
tion time of the treatment; consequently, infections 
can be related to the time of organ transplantation. 
Immunosuppressive  therapy  such  as  cyclosporine, 
glucocorticoids and antilymphocyte globulin, com-
bine to induce a broad spectrum of immune defects 
(Kotton and Fishman, 2005).
Despite significant advances in the field of renal 
transplantation, long-term graft survival is not dra-
matically  increased  (Meier-Kriesche  et  al.,  2004). 
The reasons for this are various, but include the per-
sistent impact of infectious diseases on transplant 
recipients. Viral infections continue to be a poten-
tial contributor to graft failure, and a cause of severe 
morbidity  and  mortality  (Hartmann  et  al.,  2006; 
Toyoda et al., 2005). The consequences of viral in-
fections are variable and may include direct involve-
ment of the allograft, dissemination to other organs 
or indirect effects on the patient and allograft. Some 
viruses, notably herpesviruses and polyomaviruses, 
are believed to further impair host defense, thereby 
increasing the risk for other infections. Viral infec-
tions have also been implicated as cofactors in acute 
and chronic rejection syndromes (Toyoda et al., 2005; 
Sageda et al., 2002).
According to the time elapsed since transplanta-
tion and the risk status of the patient, the post-trans-
plant period is divided into three phases: an early pe-
riod (phase one) usually lasting less than 4 weeks, a 
middle period (phase two) from the first month until 
the first year, and a late period that lasts more than 
one year from the time of transplantation. The risk 
of infection after transplantation depends on a vari-
ety of factors such as intensity, virulence and mecha-
nisms of viral exposures, the nature of the immuno-
suppressive regimen and presence or absence of pre-
existing antiviral immunity. During the first month, 
bacterial and nosocomial infections caused by anti-
microbial resistant microbes predominate. Between 
one and six months post-transplant, there is a risk 
of viral infection. Patients with a history of herpes 
simplex virus (HSV) infections may have early reac-
tivation (1 or 2 months after transplantation). Infec-
tions acquired from the donor, such as HBV, HCV or 
HIV, may also appear in the first month after surgery. 
Cytomegalovirus (CMV), both reactivation and new 
disease acquired in the middle post-transplant pe-
riod, tend to appear in months 1 to 4 or after the ces-
sation of antiviral prophylaxis (approximately by day 
100). Other latent viruses such as the Epstein Barr 
virus (EBV) and varicella zoster virus (VZV) also 
tend to appear in months 2 to 6. Half of BK polyoma-
virus nephropathy is observed in the first 6 months 
after transplantation while the other half occurs at a 
later time. Community acquired infections such as 
influenza and respiratory syncytial virus (RSV) can 
appear at any time after transplantation (Razonable 
et al., 2003). In recent years, the significance of ad-
enovirus and human metapneumovirus infections is 
increasingly recognized (Camille et al., 2005).
Viral infections remain an important cause of 
morbidity  and  mortality  in  transplant  recipients. 
They may acquire these infections from the donors 
(donor-derived infections), from reactivation of an 
endogenous latent virus, or from the general com-
munity.
The effects of viral infection are classified as ei-
ther “direct” or “indirect”. This classification helps 
in separating the effects of invasive viral infection 
(cellular and tissue injury) from effects mediated by 
inflammatory responses (e.g. cytokines) or by altera-
tions in host immune and inflammatory responses 
(Rubin, 2002; Ljungman, 2002). Syndromes such as 
fever and neutropenia (e.g. with CMV infection) or 
invasive  disease  resulting  in  pneumonia,  enteritis, 
meningitis or encephalitis are considered direct ef-
fects. Indirect effects of viral infections include re-
sponses  to  viral  infections  such  as  the  release  of 
cytokines, chemokines or growth factors. These ef-
fectors are immunomodulatory, resulting in further 
immune suppression and increased risk of other op-
portunistic infections (Boeckh and Nichols, 2003). 
In addition, viral infections alter the expression of 
surface  antigens  (e.g.  histocompatibility  antigens), 
provoking graft rejection and/or causing dysregula-
tion of cell proliferation (contributing to oncogen-
esis). Infections with one virus may cause immune 
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other viruses in a form of viral “cross-talk” (e.g. CMV 
and HCV). Multiple studies implicate infection with 
the human herpes virus (HHV) 6 and 7 as a risk fac-
tor for CMV disease, while CMV may in turn trigger 
HHV6/7 reactivation (Tong et al., 2000; Kidd et al., 
2000; Dockrell and Paya, 2001). Increased viral rep-
lication and persistence may contribute to allograft 
injury like fibrosis or chronic rejection (Babel et al., 
2001).
The risk of viral infection in these patients de-
pends on several factors, such as the type of organ 
transplanted,  the  intensity  of  immunosuppression, 
the  recipient’s  susceptibility  and  donor/recipient 
(D/R) serological status. Direct infection of allografts 
by viral pathogens is common and can cause exten-
sive damage to the graft tissue. In some cases, some 
infections  may  contribute  to  other  complications, 
such as acute or chronic rejection of the transplant 
organ. In addition to these direct effects, viral infec-
tions cause indirect effects, including a greater risk 
of the replication of other viruses, graft rejection, 
and opportunistic infections with specific entities for 
each types of transplant. These indirect effects result 
from the immunomodulatory activity of some virus-
es, such as CMV and HHV6. Solid organ and hemat-
opoietic stem cell transplant recipients are uniquely 
predisposed  to  severe  clinical  manifestations,  due 
to the variety of common and opportunistic viruses 
(Castagnola et al., 2008).
The maintenance of immunosuppressive therapy 
to prevent rejection also predisposes transplant re-
cipients to systemic infections with a range of patho-
gens. Some of these, including CMV and adenovi-
rus, can also infect the allograft, while others, such as 
Parvovirus B19, exhibit tropism for the bone marrow 
cells that typically do not involve the transplant itself. 
In renal transplant, infections are associated with a 
spectrum of glomerulonephritis, many mediated by 
immune complexes (Djamali et al., 2006).
Viral infections cause a wide variety of compli-
cations in solid organ transplant recipients, some of 
them life threatening. Herpes viruses, most notably 
CMV and EBV, are the most common among op-
portunistic viral pathogens that cause infection after 
solid organ transplantation. 
CMV  is  the  major  microbial  pathogen  with  a 
negative effect in solid organ transplant (SOT) re-
cipients. The majority of donors and recipients have 
latent CMV infection at the time of transplantation 
(Zhang et al., 1995). Furthermore, CMV is a cell-as-
sociated disease, with the viruses primarily latently 
residing  in  T  lymphocytes,  although  particles  can 
also be found in polymorphonuclear cells, endothe-
lial vascular tissue and renal epithelial cells. This cell 
specificity allows transmission of the virus within the 
transplant organ (Crumpacker and Wadhwa, 2005). 
The cytomegalovirus can substantially impact host 
immune responses. Following infection, CMV infil-
trates the cell and produces immediate-early antigens 
(Ag) that regulate DNA transcription, and during 
the next 6 to 24 h, CMV produces late Ag which di-
rect nucleocapsid protein production. It also causes 
upregulation of IL2 and downregulates MHC class 
I molecules on the surface of infected cells allowing 
them to evade host immune recognition (Brennan, 
2001). When compared with other organ transplant 
recipients,  renal  transplant  recipients  are  at  lower 
risk of CMV infection. The incidence of CMV in the 
renal transplant population is estimated to be be-
tween 8 and 32%. Donor seropositivity, especially in 
the absence of prior recipient infection, is the most 
important risk factor for post-transplant infection. 
CMV seronegative recipients of seropositive kidneys 
are at increased risk of invasive CMV disease, recur-
rent CMV, and ganciclovir-resistant CMV infection 
(Liapis et al., 2003; Paya et al., 2004). The presenta-
tion of CMV infection may be variable, ranging from 
asymptomatic infection defined by the presence of 
active viral replication to end organ or disseminated 
organ involvement (Kotton et al., 2005; Barzon et al., 
2009).
EBV is responsible for some cases of post-trans-
plant  lymphoproliferative  disorder  (PTLD),  which 
represents the most serious complication in trans-
plant recipients. It was recently recognized that pro-
liferating cells may be of either host or donor origin, 
with possible prognostic implications. Renal trans-1288 MAJA ĆUPIĆ ET AL.
plantation recipients have the lowest risk of acquir-
ing PTLD in comparison with other transplant pa-
tients (approximately 1-3%). PTLD most commonly 
occurs in the first year post-transplant. Serology for 
the presence of EBV specific antibodies should be 
obtained before transplantation. Allograft recipients 
who  are  EBV  negative  before  transplantation  and 
receive an organ from a seropositive donor are at 
greatest risk for PTLD (Green et al., 2006); conse-
quently, this is most commonly observed in pediatric 
and young adult populations. PTLD can be present 
in many organs, including the allograft itself (Opelz 
et al., 2006).
The BK polyomavirus that was first described in 
a  renal  transplant  recipient  with  ureteral  stenosis, 
has recently been recognized as an important cause 
of renal graft impairment. The prevalence of several 
forms of virus infection in allograft recipients has 
shifted considerably over the last ten years. Since the 
mid 90’s, polyoma BKV interstitial nephritis, previ-
ously rare, has become an important cause of renal 
transplant dysfunction and/or loss of graft. The BK 
virus  typically  involves  the  allograft  kidney,  with 
manifestations  including  intestinal  nephritis,  ure-
teral stenosis and ureteral stricture. Most common 
infection occurs within the first three to four months 
after transplantation, when immunosuppression is at 
its highest (Randhawa and Brennan, 2006).
The aim of this study was to determine the preva-
lence of the most important viral infections in renal 
transplant recipients: CMV, EBV and polyoma BKV 
and JCV.
MATERIALS AND METHODS
Patients
Renal transplant recipients from the Transplantation 
Center of the Clinic of Nephrology, Clinical Center of 
Serbia, Faculty of Medicine, University of Belgrade, 
were retrospectively reviewed from January 2010 to 
December 2011. Samples (plasma and urine) were 
tested for the presence of CMV, EBV and polyoma 
BKV and JCV DNA in the Virology Laboratory of 
the Institute of Microbiology and Immunology, Fac-
ulty of Medicine, University of Belgrade. A total of 
112 kidney recipients, 63 adults (36 male, median age 
45,89; range 22-63 and 27 female median age 45,44 
; range 23-60) and 49 children (33 boys, median age 
14.4; range 3-21 years, and 16 girls median age 15.81; 
range 6-21) were included in this study. All patients 
belong to the middle post-transplant period. The do-
nor/recipient CMV serological status was known for 
only 33 of the 112 transplant recipients (D/R CMV 
IgG+, IgM-). 
All 112 patients were monitored for CMV DNA, 
49 for EBV DNA in plasma samples, and 31 trans-
plant recipients were investigated for BKV and JCV 
DNA  in  plasma  samples  and  urine  using  a  PCR-
based  test.  Blood  samples  were  collected  in  5  ml 
VacutainerR tubes containing EDTA, and after cen-
trifugation DNA was extracted from 200 μl of plasma 
using the QIAmp Blood Mini Kit (QiAGEN GmBH, 
Hilden, Germany), while DNA from the urine sam-
ples was extracted using the QIAamp DNA Mini Kit 
(Qiagen,Valencia,  CA)  according  to  the  manufac-
turer’s protocols.
Isolation and amplification of viral DNA
CMV DNA was amplified using PCR targeting of 
a 435 bp region in exon 4 of the Major Immediate 
Early (MIE) gene. The amplification was performed 
using  the  following  primers:  FW  5’-CCAAGCG-
GCCTCTGATAACCAAGCC-3’ and REV 5’-CAG-
CACCATCCTCCTCTTCCTCTGG-3’.  PCR  am-
plification  was  run  in  a  reacting  volume  of  25  μl 
containing 12.5 μl PCR Master Mix (QIAgen Taq 
PCR Master Mix, Hilden Germany), 1 μl (1 μM) FW 
and 1 μl (1 μM) REV primers, 5 μl previously isolated 
DNA and 5.5 μl injection grade water. PCR was car-
ried out in a thermocycler Master Cycler Gradient 
(Eppendorf,  Germany)  following  several  steps:  an 
initial denaturation at 95oC for 5 min, followed by 35 
cycles at 95oC for 60 s, 58oC (60 s), 72oC (90s), and 
terminal elongation at 72oC for 10 min. 
For  EBV  DNA  detection,  two  different  set  of 
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within the EBNA 1 coding region (FW 5’-GTCAT-
CATCATCCGGGTCTC-3’;  REV  5’-TTCGGGTT-
GGAACCTCCTTG-3’), and the second set of prim-
ers  (FW  5’-GGCGGCTGGTGTCACCTGTGT-
TA-3’; REV 5’-CCTTAGGAGGAACAAGTCCC-3’) 
amplified a 239 bp within the gp220 coding region 
of the EBV genome. The PCR program for amplifi-
cation of EBNA1 and gp220 EBV DNA employed 
an initial denaturation step at 94˚C for 10 min, 32 
cycles of denaturation at 94˚C for 90 s, annealing at 
60˚C for 45 s and extension at 72˚C for 2 min, with a 
final extension step at 72˚C for 10 min. PCR was per-
formed using a thermocycler Master Cycler Gradient 
(Eppendorf, Hamburg, Germany). 
The 116 bp fragment within the VP2 coding re-
gion of the BKV and JCV genome was amplified by 
using a common forward primer for BKV and JCV 
(5’-TGCTCCTCAATGGATGTTGC-3’), and differ-
ent reverse primers (BKV 5’-ATTGAGGAGCAGT-
TCTT-3’; JCV 5’-CACGGGGTCCTTCCTTTC-3’). 
The PCR program, for amplification of both viruses, 
was initial denaturation at 95˚C for 5 min, 40 cycles 
of denaturation at 95˚C for 30 s, annealing at 50˚C 
for 40 s and extension at 72˚C for 1 min, with the 
final extension step at 72˚C for 10 min. 
Visualization  of  PCR  products  of  appropriate 
lengths was performed by electrophoresis in 2% aga-
rose gel stained with ethidium bromide.
Statistical analyses
The chi-square test was used for statistical analyses. P 
values <0.05 were considered statistically significant 
and P values <0.01 were considered highly statisti-
cally significant.
RESULTS
CMV DNA was tested in plasma samples in all 112 
kidney recipients (63 adults and 49 children) includ-
ed in this study. CMV DNA was detected in 14/112 
tested  renal  transplant  patients  (12.5%)  (Table  1). 
Thirteen  of  14  CMV  DNA-positive  patients  were 
adults (10 male and 3 female) and one of 14 with a 
CMV DNA-positive finding, was a child (Table 2). 
Statistical analyses between two subgroups of tested 
patients showed a highly statistically significant dif-
ference in the prevalence of CMV active infection 
between  adults  and  pediatric  patients  (χ2=8,322; 
P<0.01). On the other hand, there was no statisti-
cally significant difference in the frequency of CMV-
positive PCR between men and women (χ2=2.472; 
P>0.05). 
Forty-nine blood samples from pediatric patients 
were tested for the presence of EBV DNA by PCR 
and only 4/49 (8.16%) samples were positive (Table 
3). Three of four EBV-positive patients were younger 
than 15 years of age, and one transplant recipient 
was over fifteen years old. Statistical analyses did not 
show a significant difference in the frequency of EBV 
DNA detection in two groups of pediatric patients 
(χ2=1.340; P>0.05) (Table 4). 
Even  though  EBV  DNA  was  detected  in  four 
compared with one CMV DNA-positive result in the 
tested pediatric transplant recipients, no statistically 
significant difference between the frequency of CMV 
and EBV DNA detection was found in the pediatric 
population (χ2=1.896 P>0.05) (Table 5).
BKV and JCV DNA were detected in 13 of a to-
tal of 62 (20.9%) blood and urine samples collected 
from 31 renal transplant recipients. BKV DNA was 
detected in 10/31 (32.26%) patients while JCV DNA 
was  detected  in  3/31  (9.68%)  patients.  Statistical 
analyses  showed  that  there  was  a  statistically  sig-
nificant difference in the detection of investigated 
polyoma viruses in the kidney transplant recipients 
included in this study (χ2=4.770; P<0.05) (Table 6). 
While  these  results  suggest  that  polyoma  viruses 
viruria  (8/62;  12.9%)  represents  a  more  frequent 
finding than viremia (5/62; 8%) in renal transplant 
recipients, statistically there was no significance dif-
ference (χ2=2.296; P>0.05; χ2=1.958; P>0.05 respec-
tively) (Tables 7 and 8). 
Comparison between the groups of CMV DNA-
positive  (14/112)  and  BKV  DNA-positive  results 
(10/31), and CMV DNA (14/112) and JCV DNA-1290 MAJA ĆUPIĆ ET AL.
Table 1.  CMV DNA finding in plasma sample of investigated renal transplant patients
CMV positive CMV negative Total
Adults 13 50 63
Children 1 48 49
Total 14 98 112
χ2 =8,322
p< 0.01     
Table 2.  CMV viremia in examinated male and female renal transplant recipients
CMV positive CMV negative Total
Man 10 26 36
Women 3 24 27
Total 13 50 63
χ2 =2.472
p>0.05   
Table 3.  Epstein-Barr (EBV) viremia in tested renal transplant pediatric recipients
EBV positive EBV negative Total
Boys 3 30 33
Girls 1 15 16
Total 4 45 49
χ2 =0.111
p>0.05   
Table 4  Correlation of EBV viremia and age of renal transplant pediatric recipients
EBV positive EBV negative Total
<15 years  3 20 23
>15 years  1 25 26
Total 4 45 49
χ2 =1.340
p>0.05   
Table 5  Intergroup comparison between CMV and EBV DNA in renal transplant pediatric recipients
Positive Negative Total
EBV 4 45 49
CMV 1 47 48
Total 5 92 97
χ2 =1,896
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Table 6.  BKV and JCV PCR findings in plasma and urine samples  of tested renal transplant recipients
Positive samples Negative samples Total
BKV 10 21 31
JCV 3 28 31
Total 13 49 62
χ2 =4.770
p< 0.05  
Table 7. BKV and JCV PCR findings in urine samples of tested renal transplant recipients
Positive (urine) Negative (urine) Total
BKV 6 25 31
JCV 2 29 31
Total 8 54 62
χ2 =2,296
p>0.05   
Table 8.  BKV and JCV DNA PCR findings in plasma samples of tested renal transplant recipients
Positive (plasma) Negative (plasma) Total
BKV  4 27 31
JCV 1 30 31
Total 5 57 62
χ2 =1,958
p>0.05   
Table 9  CMV and  BKV findings in tested renal transplant recipients - intergroup comparison of prevalence of infections
Positive Negative Total
CMV 14 98 112
BKV  10 21 31
Total 24 119 143
χ2 =6,795
p<0.05   
Table 10.  CMV and JCV findings in tested renal transplant recipient - intergroup comperison of prevalence of infections
Positive Negative Total
CMV 14 98 112
JCV 3 28 31
Total 17 126 143
χ2 =0,192
p>0.05 1292 MAJA ĆUPIĆ ET AL.
positive patients (3/31), showed that there was a sta-
tistically significant difference between the frequency 
of CMV and BKV DNA detection in renal transplant 
recipients (χ2=6.795; P<0.05) (Table 9). At the same 
time,  in  the  other  comparison  groups,  CMV/JCV 
DNA-positive patients, there was no statistically sig-
nificant difference (χ2=0.196; P>0.05) (Table 10).
DISCUSSION
Viral infections are a serious complication in kidney 
transplant recipients and represent the primary cause 
of hospitalization, especially among pediatric recipi-
ents who are often seronegative at the time of trans-
plantation (Kotton and Fishman, 2005). In these pa-
tients, viral infections usually occur very soon after 
transplantation, and in many cases are transmitted 
from transplanted tissues and blood cells, where vi-
ruses exist in latency, or as a result of active infec-
tions of the donor that are unrecognized at the time 
of organ procurement (Fishman, 2007). The presence 
of viruses in the graft depends on their tropism for 
specific tissues and cells and their ability to establish 
latency or persistent infection. This is the case for vi-
ruses such as CMV, EBV and recently demonstrated 
polyoma BKV and JCV (Barzon et al., 2009) that can 
cause, besides life-threatening diseases, injury of the 
renal graft.
CMV remains the most important viral patho-
gen after transplantation despite the availability of 
effective antiviral drugs and validated strategies for 
prophylactic,  preemptive  and  therapeutic  therapy. 
CMV can affect almost every organ and system, with 
frequent recurrences and increasing rates of antiviral 
resistance. Together with indirect long-term effects, 
CMV significantly reduces graft and patient survival 
after solid organ transplantation. According to the 
results of Blair and Blumberg (2008), the prevalence 
of CMV infection in renal transplant recipients is 
estimated to be between 8% and 32%. Results from 
this study showed that the prevalence of CMV ac-
tive infection is 12.5% (14/112 patients were CMV 
DNA positive). Also, findings from this study indi-
cate a statistically significant difference in the preva-
lence of CMV DNA-positive results in plasma sam-
ples between adults and pediatric kidney transplant 
recipients (χ2=8.322; P< 0.01). However, there is no 
statistically significant difference in the prevalence of 
CMV infection between genders. 
The identification of patients at high risk for CMV 
replication according to the serostatus of donor and 
recipients provides the rationale for prophylactic and 
preemptive administration of antivirals and signifi-
cantly reduces CMV disease and associated morbid-
ity (Egli et al., 2007). 
Serological screening for CMV antibodies should 
be performed on both donors and recipients before 
transplantation to identify patients at risk for infec-
tion after transplantation who might benefit from 
a preventive strategy. CMV prevention must be in-
dividualized by risk group and immunosuppressive 
regimen. Patients at risk for primary infection (D+/
R-) are generally given valganciclovir prophylaxis for 
3-6 months after transplantation, while 6 months of 
prophylaxis is often used in patients (D+/R- or R+) 
receiving depleting antilymphocyte antibodies (Tab-
er et al., 2004). Patients at lower risk (R+) may also 
be followed-up using quantitative assays at prede-
fined intervals (weekly) to detect and treat early dis-
ease (preemptive therapy). In renal transplant recipi-
ents receiving either prophylaxis (oral ganciclovir) or 
weekly PCR surveillance and treatment for either a 
positive assay or invasive disease, using prophylaxis 
was more effective at preserving renal function and 
had the lowest risk of rejection (Geddes et al., 2003). 
Two main strategies are employed to prevent CMV. 
The first, so-called universal prophylaxis (to prevent 
infection before its onset), is used for all patients at 
risk of disease (D+/R+) and is continued for a set pe-
riod of time. The second, known as targeted prophy-
laxis, focuses its strategies on those at highest risk for 
the disease (D+/R-). An alternative to prophylaxis is 
a preemptive strategy that employs periodic screen-
ing for occult CMV viremia and initiation of early 
treatment (Green et al., 2004).
EBV has a central role in the pathogenesis of 
post-transplant lymphoproliferative disease (PTLD), 
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and Keay, 2001). Under conditions of severe T cell 
immunosuppression, which dominate in transplant 
patients,  EBV-infected  B  cells  may  expand  unre-
stricted,  resulting  in  malignant  lymphoprolifera-
tion. In this context, the virus is able to transform 
and  immortalize  B-lymphocytes,  leading  to  their 
uncontrolled proliferation. This is particularly likely 
in settings where the host lacks adequate cytotoxic 
T lymphocyte surveillance. One such setting occurs 
when transplant recipients experience primary EBV 
infection.  The  majorities  of  these  tumors,  known 
collectively as B cell lymphoproliferative disorders 
or post transplantation lymphoproliferative disease, 
when present in transplant recipients, are EBV-asso-
ciated and often occur within the first year following 
transplantation (Allen et al., 2002).
Primary EBV infection is a major risk factor for 
the development of these tumors; however, PTLD 
has also been documented in patients with reactivat-
ed infection. Thus, the incidence of PTLD is greater 
in children than in adults, with rates of 4% to 22% 
reported for the various categories of pediatric organ 
transplant recipients versus an average of 1% to 2% 
in adults (Green, 2001). 
In this study, EBV DNA was obtained and de-
tected only in the pediatric renal transplant recipi-
ents. Four of 49 (8.16%) pediatric kidney transplant 
recipients had an EBV-positive finding in the tested 
plasma samples. EBV DNA was not detected in the 
tested samples obtained from adult renal transplant 
recipients.
This difference between adults and children is 
understandable in view of the fact that in EBV-se-
ronegative transplant recipients EBV infection rates 
are  high,  approaching  100%  within  three  months 
after transplantation (Allen et al., 2001). Children 
are more likely to contract a primary EBV infection 
after transplantation, usually from the donor organ 
or blood transfusions (Savoie et al., 1994; Ho et al., 
1988),  because  many  are  EBV-seronegative  before 
transplantation. In developed countries, EBV sero-
positivity rates increase with age; therefore, in the 
general population of children from 1 to 18 years of 
age, up to 50% are EBV-seropositive, compared with 
a 90% seropositivity rate in adults (Allen et al., 2002; 
Burra et al., 2006). 
EBV serology is important for pre-transplanta-
tion identification of the risk factors for PTLD (e.g. 
the identification of D+R– subjects). Knowing this, 
the risk of PTLD may decrease if it were possible 
to  give  EBV-seronegative  recipients  EBV-seroneg-
ative organs. However, the form of donor-recipient 
matching is often not a practical preventive strategy, 
because of the limited supply of donor organs (Allen 
et al., 2002). Serology has limited or no value after 
transplantation unless it is part of an evaluative study. 
The main component of laboratory surveillance for 
EBV-related diseases after transplantation revolves 
around the use of sequential PCR testing to docu-
ment the presence of infection and the magnitude of 
EBV load. Serological tests are of limited value (Tsai 
et al., 2002).
The  human  polyomavirus  BKV  has  only  re-
cently surfaced as a pathogen with organ tropism 
largely limited to the renourinary tract, manifesting 
as a polyomavirus-associated nephropathy in kidney 
transplant recipients. Transmission of BKV occurs 
typically during childhood (median 4-5 years of age) 
via oral and respiratory routes, but data suggesting 
transmission via cells and tissues, in particular by 
kidney transplantation, have been reported (Know-
les et al., 2003). Seroprevalence increases more than 
80% in adults (Hirsch et al., 2006). After primary rep-
lication in seronegative individuals, BKV establishes 
non-replicative infection in the renourinary system, 
without known complications for the immunocom-
petent host. In about 5% of healthy individuals, in-
termittently reactivation with detectable viruria of 
BKV occurs (Dolei et al., 2000). 
Polyomavirus  associated  nephropathy  (PVAN) 
and late-onset hemorrhagic cystitis are major com-
plications  linked  to  high-level  BKV  replication  in 
kidney transplant recipients (Allander et al., 2007). 
Recently many investigators have studied the impor-
tant role of BKV in PVAN. PVAN complicates kidney 
transplantation in 1-10% of cases, usually at the end 1294 MAJA ĆUPIĆ ET AL.
of the first year post-transplantation, with clinically 
silent, creeping allograft failure in 50-90%. Graft loss 
may occur in around 50% of cases during the sub-
sequent 6-60 months. Persisting BKV replication is 
associated with a higher probability of graft loss.
According to the results of this study, the prev-
alence of BKV (32.65%) is much higher than the 
prevalence of JCV (9.68%) in immunocompromised 
patients. Although viruria of both polyomaviruses is 
more frequent in kidney recipients than viremia, re-
sults from this study did not show a statistically sig-
nificant difference between polyomaviruses viruria 
and viremia (12.9% and 8%, respectively).
Therefore, testing for the presence of BKV DNA 
in  the  urine  has  become  the  most  pivotal  test  to 
exclude PVAN in 65-85% of kidney transplant pa-
tients, whereas in patients with detectable viruria, 
plasma BKV loads allow the diagnosis of ‘‘presump-
tive PVAN’’ in cases with confirmed higher values 
to the equivalent of >10 000 copies/ml. Screening 
for BKV DNA is therefore recommended every 3 
months during the first 2 years post-transplantation, 
when allograft biopsies are performed for any rea-
son, or when allograft dysfunction occurs (Hirsch et 
al., 2005). Currently, reducing immunosuppression 
is considered to be the intervention of choice. The 
absence of effective anti-polyomaviral drugs renders 
BKV treatment strategies largely dependent on the 
immunological containment of BKV replication. As-
says quantifying virus-specific cellular immune re-
sponses in real-time are important new avenues to 
be explored to better predict the risk of replication 
and  disease  and  to  optimize  clinical  management 
(Hirsch, 2006).
CONCLUSION
The study of viral infectious diseases associated with 
transplantation focuses on the prevention of infec-
tion in transplant recipients. The interaction between 
infection and immunosuppression after transplanta-
tion has a crucial role. The induction of immuno-
logical tolerance might, if successful, reduce the risk 
of  viral  infection  after  transplantation.  However, 
two caveats remain. Firstly, exposures to infections 
subsequent to the development of tolerance might 
abrogate  tolerance  and  induce  allograft  rejection. 
Secondly, the induction of tolerance to an allograft 
might induce immunologic unresponsiveness to la-
tent microorganisms in the organ.
Techniques  currently  under  development,  in-
cluding more sensitive microbiology assays and im-
munoassays, can provide the potential for individual-
ized immunosuppression and prophylactic strategies. 
Such assays may ultimately permit a more dynamic 
assessment of the immune status of transplant recipi-
ents over time, allowing titration of immunosuppres-
sion and reducing serious illness or death from viral 
infection and/or malignant conditions. 
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